These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
33. [The role of fosfomycin in the management of urinary tract infections]. Zaitsev AV; Kolontarev KB Urologiia; 2017 Sep; (4):91-96. PubMed ID: 28952700 [TBL] [Abstract][Full Text] [Related]
34. Treatment of respiratory infections with fosfomycin. Menéndez A; Tutor A; Sousa AS Chemotherapy; 1977; 23 Suppl 1():348-57. PubMed ID: 832536 [TBL] [Abstract][Full Text] [Related]
35. Fosfomycin for Treatment of Prostatitis: New Tricks for Old Dogs. Grayson ML; Macesic N; Trevillyan J; Ellis AG; Zeglinski PT; Hewitt NH; Gardiner BJ; Frauman AG Clin Infect Dis; 2015 Oct; 61(7):1141-3. PubMed ID: 26063723 [TBL] [Abstract][Full Text] [Related]
36. Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of fosfomycin for the treatment of patients with systemic infections. Roussos N; Karageorgopoulos DE; Samonis G; Falagas ME Int J Antimicrob Agents; 2009 Dec; 34(6):506-15. PubMed ID: 19828298 [TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetics, Safety, and Tolerability of Single-Dose Intravenous (ZTI-01) and Oral Fosfomycin in Healthy Volunteers. Wenzler E; Ellis-Grosse EJ; Rodvold KA Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630194 [TBL] [Abstract][Full Text] [Related]
38. A randomized comparative study of single-dose fosfomycin and 5-day ciprofloxacin in female patients with uncomplicated lower urinary tract infections. Ceran N; Mert D; Kocdogan FY; Erdem I; Adalati R; Ozyurek S; Goktas P J Infect Chemother; 2010 Dec; 16(6):424-30. PubMed ID: 20585969 [TBL] [Abstract][Full Text] [Related]